Breast Cancer Trial Adapts to Treatment Changes: BioNTech Plans to Combine Trodelvy With a Bispecific Antibody
ROSETTA Breast-01 plans to use an antibody-drug conjugate as its treatment backbone to test whether adding pumitamig can further improve survival in patients with advanced triple-negative breast cancer. The trial amendment remains subject to regulatory approval, and the benefits and risks of the combination have yet to be established.